

Physiological and pharmacological implications of AT₁ versus AT₂ receptors

OLIVER CHUNG, HENDRIK KÜHL, MONIKA STOLL, and THOMAS UNGER

Institute of Pharmacology, University of Kiel, Kiel, Germany, and Medical College of Wisconsin, Madison, Wisconsin, USA

Physiological and pharmacological implications of AT₁ versus AT₂ receptors. Angiotensin II (Ang II) has diverse physiological actions that lead, for instance, to increases in extracellular volume and peripheral vascular resistance and blood pressure, and it has also been implicated in the regulation of cell growth and differentiation. Molecular cloning and pharmacological studies have defined two major classes of Ang II receptors, designated AT₁ and AT₂. Most effects of Ang II are mediated by AT₁ receptors. Much less is known about the physiological role of AT₂ receptors. Recent evidence suggests involvement of AT₂ receptors in development, cell differentiation, apoptosis, and regeneration in various tissues. AT₁ and AT₂ receptors have been shown to exert counteracting effects on cellular growth and differentiation, vascular tone, and the release of arginine vasopressin. In each condition, the AT₂ receptor appears to down-modulate actions mediated by the AT₁ receptor, resulting in decreased cellular proliferation, decreased levels of serum arginine vasopressin levels, or decreased vasoconstrictor responses. In addition, in neuronal cell lines, the AT₂ receptor exerts antiproliferative actions and promotes neurite outgrowth, an effect accompanied by significant changes in the expression pattern of growth/differentiation-related genes.

The octapeptide angiotensin II (Ang II) is the major effector of the renin-angiotensin system (RAS) and exerts a wide range of actions. Besides its physiological contribution to cardiovascular, renal, and endocrine functions and its osmoregulatory role in the central nervous system, Ang II plays a major role in the pathogenesis of hypertension and is also considered an important factor in cardiovascular pathology, such as cardiac left ventricular hypertrophy and fibrosis, vascular media hypertrophy, or neointima formation and structural alterations of the heart and kidney, such as postinfarct remodeling and nephrosclerosis. Recently, Ang II has also been implicated in cell growth and differentiation. In the kidney, for example, Ang II is involved in angiogenesis occurring during glomerular differentiation [1] and nephrosclerosis [2]. Furthermore, the role of Ang II

as a growth factor has been demonstrated in studies on fibroblasts, adrenal cortical, vascular smooth muscle (VSM), or cardiac cells, and growth-modulating effects have been shown also in mesangial and tubular cells of the kidney [3, 4].

ANGIOTENSIN II RECEPTOR SUBTYPES

The development of highly specific and selective AT₁ receptor antagonists, such as losartan, valsartan, eprosartan, irbesartan, candesartan, telmisartan, and others [5, 6], and AT₂ receptor ligands/antagonists, such as PD123177, PD123319, and CGP42112 [6, 7], was the basis for the identification and characterization of Ang II receptor subtypes. Two main Ang II receptor subtypes have been characterized, AT₁ and AT₂, which are heterogeneously distributed in peripheral tissues and in the brain (Table 1) [5, 8–10]. In humans, only a single gene encoding for the AT₁ receptor is expressed, which is localized on chromosome 3. In rodents, however, AT_{1a} and AT_{1b} receptor isoforms exist, which are localized on chromosomes 17 and 2, respectively. They show 91% similarity for nucleic acid and 96% similarity for amino acids [11, 12]. Although AT_{1a} and AT_{1b} subtypes seem to be more or less equally expressed in spleen, liver, and kidneys [4, 11, 12], the AT_{1a} receptor seems to predominate in VSM, heart, lung, ovary, and hypothalamus [4, 11–14]. The fact that AT_{1a} predominates in VSM suggests that this subtype plays a role in vasoconstriction. On the other hand, as the AT_{1b} receptor subtype seems to prevail in the anterior pituitary, adrenal gland, uterus, and several periventricular brain areas [4, 12–15], this receptor may be involved in hormonal secretion and central osmotic control. In humans and mice, the genes for the AT₂ receptor are localized on the X-chromosome. Both AT₁ and AT₂ receptors belong to the seven-transmembrane-domain superfamily of receptors, but the nucleic acid sequence of the AT₁ receptor has only 34% identity with the AT₂ receptor sequence. The AT₂ receptor is found ubiquitously in fetal tissues. In the adult organism, this receptor is expressed highly in the adrenal medulla, uterus, and ovary, and is also found in vascular endothelium and certain areas of the brain [4, 10, 16, 17]. The fact

Key words: angiotensin II, angiotensin receptors, renin angiotensin system, receptor antagonists, hypertension, growth factors.

© 1998 by the International Society of Nephrology

Table 1. AT₁ and AT₂ receptors and their distribution

	AT ₁ receptor	AT ₂ receptor
Distribution	Widely distributed in adult tissues, e.g., blood vessels, kidney, adrenal gland, heart, liver, brain	Widely distributed in fetal tissues, expression in the adult brain, adrenal glands, ovary, uterus, endothelium, myocardium
Function	Vasoconstriction, cardiac contractility, aldosterone release, glomerular filtration, renal blood flow, cardiac and vascular hypertrophy, central osmoregulation	Possible role in growth and development (antiproliferation, inhibition of neointima, cell differentiation)
Structure	Seven-transmembrane-receptor, G-protein-coupling	Seven-transmembrane-receptor, G-protein-coupling
Ligands	Losartan, valsartan, irbesartan, candesartan, eprosartan, telmisartan, tasosartan	PD 123177, CGP 42112A, PD 123319
Isoforms	AT _{1a} , AT _{1b}	?

that the AT₂ receptor is expressed at high levels in embryonic tissues but much less so in normal adult tissues has prompted speculation on its possible role in cell growth and differentiation. The presence of different subtypes for the AT₂ receptor and the existence of AT₃ and AT₄ receptor subtypes are still controversial [18–23].

THE AT₁ RECEPTOR

The AT₁ receptor reportedly interacts with various G proteins and is coupled to one of the two heteromeric G proteins: G_{qα} or G_{iα}. Ang II binding to specific sites of the extracellular and membrane-spanning portions of the AT₁ receptor releases the α subunit of the G protein and subsequently activates phospholipase C via G_q or inhibits adenylate cyclase via G_i. Phospholipase C activation generates 1,4,5-inositol trisphosphate and diacylglycerol, with subsequent activation of protein kinase C and an increase in intracellular [Ca²⁺] via L-type Ca²⁺ channels [24–26]. The rise in intracellular [Ca²⁺] is accompanied by typical AT₁ receptor-associated responses such as vasoconstriction, renal salt and water retention, aldosterone and vasopressin release, effects on glomerular filtration rate, and renal blood flow, as well as the Ang II-mediated stimulation of cell growth. Protein kinase C and elevated intracellular [Ca²⁺] promote expression of growth-related inducible transcription factors, such as, *c-fos*, *c-myc*, and *c-jun* [27]. The proteins encoded by the growth-related inducible transcription factors act as transcription factors for various target genes, which may be involved in the stimulation of mitogenesis. Ang II also induces, via the AT₁ receptor, transcription of platelet-derived growth factor-A chain and transforming growth factor-β₁ and so is coupled directly to growth factor expression [28, 29]. It was shown recently that stimulation of AT₁ receptors in VSM cells (VSMCs) induces rapid phosphorylation of tyrosine in the intracellular kinases Jak2 and Tyk2 and that this phosphorylation is associated with increased Jak2 activity [30]. This is significant, because the Jak-STAT pathway may be the signaling mechanism used by cell surface-binding cytokines responsible for transcriptional activation of early growth response

genes [31]. This pathway may thus play an additional role in the control of AT₁-mediated cell growth.

VSMCs in culture, a cell line commonly used for studying trophic effects of Ang II, express only AT₁ receptors, and consequently, trophic effects shown in these cells can be mediated only by AT₁ receptors [17]. In all experiments on these cells, AT₂ receptor ligands are ineffective. The growth responses of VSMCs to Ang II vary with the particular VSMC studied, and the mechanisms leading to differential growth responses are still controversial. Dzau et al have proposed that Ang II represents a bifunctional growth factor for VSMCs by simultaneously stimulating proliferative and antiproliferative pathways that appear to be mediated by the activation of platelet-derived growth factor-AA and transforming growth factor-β₁, respectively, thereby shifting the balance in favor of hypertrophy instead of hyperplasia in some instances [32].

Compared with AT₂ receptors, AT₁ receptors dominate by far in the adult human [33] and rat [34] kidneys; only 5% to 10% of the Ang II receptors are AT₂. This predominance of AT₁ receptors might in part explain why angiotensin converting enzyme (ACE) inhibitors and AT₁ antagonists act very similarly in the kidney [35]. AT₁ antagonists can also vasodilate the renal vessels, particularly the glomerular efferent (and afferent) arterioles, increase cortical renal plasma flow [36, 37], and enhance glomerular filtration rate via a contraction of mesangial cells. Beneficial effects, in extent comparable to those of ACE inhibitors, on proteinuria, microproteinuria, and diabetes-induced changes of the kidney have also been described for AT₁ antagonists [38], and in spontaneously hypertensive rats, AT₁ antagonists improve cardiac and vascular structure and function similar to ACE inhibitors [39].

In newborn rat kidneys, AT₁ mRNA occurs in glomeruli, vessels, and nephrogenic cortex, areas where cell proliferation and differentiation occur simultaneously. Blockade of the AT₁ receptor in newborn rats arrests nephrovascular maturation and renal growth, resulting in altered kidney architecture, characterized by fewer, thicker, and shorter afferent arterioles, reduced glomerular size and number,

and tubular dilation [1]. When the mouse AT_{1a} receptor gene is disrupted in embryonic stem cells (AT₁ knockout), however, the deletion is not lethal, and mice are born in expected numbers with normal vasculature, kidneys, and hearts but significantly lower blood pressure [40]. This suggests that the effects of AT₁ receptor blockade on renal structure and function might not only be due to blockade of the AT₁ receptor itself. Actions of the unopposed AT₂ receptor may contribute, as AT₁ receptor antagonists do not affect the AT₂ receptor (and potentially other angiotensin receptor subtypes) but even expose it to increased Ang II levels. The latter is due to the loss of the negative feedback exerted by Ang II via the AT₁ receptor on renin release, and hence on its own generation. It is thus conceivable that under blockade of AT₁ receptors, Ang II interactions with other unopposed Ang II receptors, such as AT₂, are intensified, contributing to the beneficial effects on cardiac and vascular structure seen with AT₁ antagonists [17, 41].

THE AT₂ RECEPTOR

In contrast to the AT₁ receptor, much less is known about the structural and functional properties of the AT₂ receptor. Although this Ang II receptor subtype has been cloned recently [42, 43], its molecular structure and signal transduction pathway are far from completely understood. The rat AT₂ receptor cDNA encodes for a 363-amino acid protein that has a seven-transmembrane topology and 34% homology in nucleic acid sequence to the AT₁-receptor. However, it is still controversial whether the AT₂ receptor is coupled to G proteins and how it signals. Kambayashi et al have reported that the rat AT₂ receptor inhibits a phosphotyrosine phosphatase in COS-7 cells stably expressing the rat AT₂ receptor [42]. This effect is dependent on a pertussis-toxin—sensitive, G-protein—coupled mechanism. Further evidence in support of AT₂ receptor coupling to G proteins has been provided by Kang et al who have shown that G_i (but not G_o) is involved in AT₂ receptor-mediated modulation of K⁺ channels in rat primary cultures of neuronal origin [44]. On the other hand, Mukoyama et al have reported that the rat AT₂ receptor shares a seven-transmembrane domain topology that may belong to a unique class of seven-transmembrane receptors for which G-protein coupling has not been demonstrated [43]. In their studies, stimulation of the cloned AT₂ receptor, transiently expressed in COS-7 cells, failed to increase 1,4,5-inositol trisphosphate or intracellular [Ca²⁺], and no apparent effects on cAMP and cGMP levels or phosphotyrosine phosphatase activity could be observed. In NG 108-15 cells, which express AT₂ receptors constitutively, AT₂ receptor stimulation inhibits T-type Ca²⁺ channels through an as yet undefined pathway [26]. In another cell line, PC12W, which only expresses AT₂ receptors, Ang II stimulates a membrane-associated phosphotyrosine phosphatase and inhibits atrial natriuretic peptide-sensitive

particulate guanylate cyclase via a G-protein—dependent pathway [28, 45].

The relationship between AT₂ receptor-mediated signaling and tyrosine phosphorylation [42, 45] and the fact that the AT₂ receptor subtype is highly and transiently expressed in fetal tissues followed by a dramatic decrease in most organs just after birth [46] suggests that this receptor plays a role in physiological processes involving cellular growth, differentiation, and adhesion. Recent studies in our laboratory demonstrate that angiotensin peptides can exert an antimitogenic action on rat and bovine endothelial cells of different origin via the AT₂ receptor, suggesting that Ang II has different growth-modulating actions depending on the presence or absence of Ang II receptor subtypes on a given cell [17, 47, 48]. In further studies in PC12W cells, we also demonstrated that Ang II inhibits fetal calf serum- and epidermal growth factor-induced proliferation and potentiated nerve growth factor- and epidermal growth factor-mediated growth inhibition via the AT₂ receptor [41, 49, 50]. This effect is obviously not AT₂-mediated, as *c-fos* and *c-jun* mRNA expression are not inhibited through the AT₂ receptor [51]. Our results are supported by recent findings by Nakayima et al [52] who have attempted to characterize the role of the AT₂ receptor in the model of neointima formation in the balloon-injured rat carotid artery. In this *in vivo* gene transfer study, the AT₂ receptor was transfected to the injured vessel, and the formation of neointima was studied in the presence or absence of the AT₂ receptor. Morphometric analysis performed 14 days after balloon injury revealed that myointimal size was reduced by 70% in the presence of the AT₂ receptor. This effect could be reversed by the AT₂ antagonist PD 123319, suggesting that the expressed AT₂ receptor mediated the inhibiting effect on neointima formation.

Siragy and Carey [53] recently have reported that prostaglandin E₂ (PGE)₂ and cGMP levels in the renal interstitial fluid were not altered by AT₁ and/or AT₂ receptor blockade during normal sodium intake in rats. However, under conditions of sodium depletion, the AT₂ antagonist PD123319 inhibited the increase in cGMP engendered by dietary sodium. Treatment with the AT₁ antagonist losartan had no effect on cGMP but significantly decreased PGE₂, whereas PD123319 further increased PGE₂ levels. A combined blockade with losartan and PD123319 decreased both PGE₂ and cGMP. These findings suggest that under conditions of a stimulated renal RAS, but not under normal conditions, the AT₁ receptor promotes renal production of PGE₂, whereas the AT₂ receptor mediates cGMP production. These data imply an interaction between AT₁ and AT₂ receptors with respect to the production and release of these intermediators. These findings are supported by data obtained in spontaneously hypertensive rats, in which AT₂ receptor-mediated stimulation of the bradykinin/nitric oxide system can account for effects of AT₁ receptor blockade on aortic cGMP [54]. Postnatal blockade of AT₂ receptors

in newborn rats does not alter nephrovascular growth or maturation [3], a finding consistent with AT₂ receptors being abundant during fetal life but disappearing soon after birth [46, 55, 56]. Along these lines, AT₂ mRNA in rat kidney is expressed in undifferentiated nephrogenic mesenchymal tissue but not in the immature and mature glomeruli and tubules from day 12 of fetal life to day 15 postpartum, disappearing totally after day 22 postpartum [55, 57]. However, AT₂ receptors can be reexpressed under pathophysiological conditions involving tissue remodeling or repair, such as in vascular neointima formation, post-myocardial infarction, or nerve injury as well as apoptosis [4, 58], to control excessive growth mediated via the AT₁ receptor or by other growth factors. These findings, together with the fact that the AT₂ receptor exerts growth-inhibiting effects on neuronal and endothelial cells [17, 41] and displays a growth-dependent regulation in cultured rat mesangial cells [59], suggest that the AT₂ receptor has general significance for cell growth and differentiation.

SUMMARY

The characterization of the Ang II receptor subtypes offers new tools to advance knowledge on the various functions of Ang II. Recently, AT₁ receptor antagonists have been introduced as orally active antihypertensive drugs. They block AT₁ receptors specifically with low toxicity and high therapeutic safety, and improve cardiac and vascular structure and function similarly to ACE inhibitors. The mechanisms for these additional effects of AT₁ blockers are not yet understood. Besides blood pressure reduction, blockade of the AT₁ receptor may prevent the hypertrophic effects of Ang II with the help of the AT₂ receptor. Furthermore, we could show that Ang II also exerts differential growth-modulating actions depending on the presence or absence of the receptor subtypes on a given cell. Stimulation of AT₁ receptors results in cell growth and/or proliferation, whereas stimulation of AT₂ receptors inhibits cell proliferation. Moreover, there is evidence that AT₁ and AT₂ receptors counteract each other by an as yet unknown mechanism with respect to cell proliferation and differentiation.

APPENDIX

Abbreviations used in this article are: ACE, angiotensin converting enzyme; Ang II, angiotensin II; PGE₂, prostaglandin E₂; RAS, renin-angiotensin system; VSM, vascular smooth muscle; VSMCs, vascular smooth muscle cells.

Reprint requests to Thomas Unger, M.D., Institute of Pharmacology, University of Kiel, Hospitalstr. 4, D-24105 Kiel, Germany.
E-mail: th.unger@pharmakologie.uni-kiel.de

REFERENCES

1. TUFRO-MCREDDIE A, ROMANO LM, HARRIS JM, FERDER L, GOMEZ A: Angiotensin II regulates nephrogenesis and renal vascular development. *Am J Physiol* 269:F110-F115, 1995

2. LAFAYETTE RA, MAYER G, PARK SK, MEYER TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. *J Clin Invest* 90:766-771, 1992
3. TIMMERMANS PBMWM, WONG PC, CHIU AT, HERBLIN RR, SAYE JAM, SMITH RD: Angiotensin II receptors and angiotensin II receptor antagonists. *Pharmacol Rev* 45:205-251, 1993
4. UNGER T, CHUNG O, CSIKOS T, CULMAN J, GALLINAT S, GOHLKE P, HOHLE S, MEFFERT S, STOLL M, STROTH U, ZHU YZ: Angiotensin receptors. *J Hypertens* 14(Suppl 4):S95-S103, 1996
5. CHIU AT, HERBLIN WF, MCCALL DE, ARDECKY RJ, CARINI DJ, DUNCIA JV, PEASE LJ, WONG PC, WEXLER RR, JOHNSON AL, ET AL: Identification of angiotensin II receptor subtypes. *Biochem Biophys Res Commun* 165:196-203, 1989
6. TIMMERMANS PBMWM, WONG PC, CHIU AT, HERBLIN WF, BENFIELD P, CARINI DJ, LEE RJ, WEXLER RR, SAYE JA, SMITH RD: Angiotensin II receptors and angiotensin II receptor antagonists. *Pharmacol Rev* 32:135-165, 1993
7. TIMMERMANS PBMWM, WONG PC, CHIU AT, HERBLIN WF: Nonpeptide angiotensin II receptor antagonists. *Trends Pharmacol Sci* 12:55-61, 1991
8. OBERMÜLLER N, UNGER T, CULMAN J, GOHLKE P, BOTTARI SP: Distribution of angiotensin II receptor subtypes in rat brain nuclei. *Neurosci Lett* 132:11-15, 1991
9. TSUTSUMI K, SAAVEDRA JM: Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. *Am J Physiol* 261:R209-R216, 1991
10. TIMMERMANS PBMWM, CHIU AT, HERBLIN WF, WONG PC, SMITH RD: Angiotensin II receptor subtypes. *Am J Hypertens* 5(Suppl 6, pt 1):406-410, 1992
11. KAKAR SS, SELLERS JC, DEVOR DC, MUSGROVE LC, NEILL JD: Angiotensin II type-1 receptor subtype cDNAs: Differential tissue expression and hormonal regulation. *Biochem Biophys Res Commun* 183:1090-1096, 1992
12. SANDBERG K, JI H, CLARK AJL, SHAPIRA H, CATT KJ: Cloning and expression of a novel angiotensin II receptor subtype. *J Biol Chem* 267:9455-9458, 1992
13. CHIU AT, DUNSCOMB JH, MCCALL DE, BENFIELD P, BAUBONIS W, SAUER B: Characterization of angiotensin AT1a receptor isoform by its ligand binding signature. *Regul Pept* 44:141-147, 1993
14. KAKAR SS, RIEL KK, NEILL JD: Differential expression of angiotensin II receptor subtype mRNAs (AT-1A and AT-1B) in the rat brain. *Biochem Biophys Res Commun* 185:688-692, 1992
15. KITAMI Y, OKURA T, MARUMOTO K, WAKAMIYA R, HIWADA K: Differential gene expression and regulation of type-1 angiotensin II receptor subtypes in the rat. *Biochem Biophys Res Commun* 188:446-452, 1992
16. STECKELINGS UM, BOTTARI SP, UNGER T: Angiotensin receptor subtypes in the brain. *Trends Pharmacol Sci* 13:365-368, 1992
17. STOLL M, STECKELINGS UM, PAUL M, BOTTARI SP, METZGER R, UNGER T: The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. *J Clin Invest* 95:651-657, 1995
18. WRIGHT JW, HARDING JW: Brain angiotensin receptor subtypes in the control of physiological and behavioral responses. *Neurosci Biobehav Rev* 18:21-53, 1994
19. CHAKI S, INAGAMI T: Identification and characterization of a new binding site for angiotensin II in mouse neuroblastoma neuro-2A cells. *Biochem Biophys Res Commun* 182:388-394, 1992
20. HALL KL, VENKATESWARAN S, HANESWORTH JM, SCHELLING ME, HARDING JW: Characterization of a functional angiotensin IV receptor on coronary microvascular endothelial cells. *Regul Pept* 58:107-115, 1995
21. JARVIS MF, GESSNER GW, LY CG: The angiotensin hexapeptide 3-8 fragment potently inhibits ¹²⁵I-angiotensin II binding to non AT1 or AT2 recognition sites in bovine adrenal cortex. *Eur J Pharmacol* 219:319-322, 1992
22. SARDINIA MF, HANESWORTH JM, KREBS LT, HARDING JW: AT4 receptor binding characteristics: D-amino acid and glycine-substituted peptides. *Peptides* 14:949-954, 1993
23. ROBERTS KA, KREBS LT, KRAMÁR EA, SHAFFER MJ, HARDING JW, WRIGHT JW: Autoradiographic identification of brain angiotensin IV

- binding sites and differential *c-fos* expression following intracerebroventricular injection of angiotensin II and IV in rats. *Brain Res* 682:13–21, 1995
24. BOTTARI SP, TAYLOR V, KING IN, BOGDAL S, DE GASPARO M: Angiotensin II AT₂ receptors do not interact with guanine nucleotide binding proteins. *Eur J Pharmacol* 207:157–163, 1991
 25. GARRISON JC, JOHNSON DE, CAMPANILE CP: Evidence for the role of phosphorylase kinase, protein kinase C and other Ca²⁺-sensitive protein kinases in the response of hepatocytes to angiotensin II and vasopressin. *J Biol Chem* 259:3283–3292, 1988
 26. BUISSON B, BOTTARI SP, DE GASPARO M, GALLO PN, PAYET MD: The angiotensin II AT₂ receptor modulates T-type calcium current in non-differentiated NG 108–15 cells. *FEBS Lett* 309:161–164, 1992
 27. KAWAHARA Y, SUNAKO M, TSUDA T, FUKUZAKI H, FUKUMOTO Y, TAKAI Y: Angiotensin II-induced expression of the *c-fos* gene through protein kinase C activation and calcium ion mobilization in cultured vascular smooth muscle cells. *Biochem Biophys Res Commun* 150:52–59, 1988
 28. BRECHLER V, REICHLIN S, DE GASPARO M, BOTTARI SP: Angiotensin II stimulates protein tyrosine phosphatase activity through a G-protein-independent mechanism. *Recept Channels* 2:89–97, 1994
 29. STOUFFER GA, OWENS GK: Angiotensin II-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor β_1 . *Circ Res* 70:820–828, 1992
 30. MARRERO MB, SCHIEFFER B, PAXTON WG, HEERDT L, BERK BC, DELAFONTAINE P, BERSTEIN KE: Direct stimulation of Jak/STAT pathway by the angiotensin II AT₁ receptor. *Nature* 375:247–250, 1995
 31. DARNELL JE, KERR IM, STARK GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. *Science* 264:1415–1421, 1994
 32. DZAU VJ, GIBBONS GH, PRATT RE: Molecular mechanisms of vascular renin-angiotensin-system in myointimal hyperplasia. *Hypertension* 18(Suppl 2):100–105, 1991
 33. CHANSEL D, CZEKALSKI S, PHAM P, ARDAILLOU R: Characterization of angiotensin II receptor subtypes in human glomeruli and mesangial cells. *Am J Physiol* 262:F432–F441, 1992
 34. ZHUO J, ALCORN D, HARRIS PJ, MENDELSON FAO: Localization and properties of angiotensin II receptors in rat kidney. *Kidney Int* 44(Suppl 42):S40–S46, 1993
 35. BURNIER M, ROCH-RAMEL F, BRUNNER HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. *Kidney Int* 49:1787–1790, 1996
 36. LO M, LIU KL, LANTELME P, SASSARD J: Subtype 2 of angiotensin II receptors controls pressure-natriuresis in rats. *J Clin Invest* 95:1394–1397, 1995
 37. KEISER JA, BJORK FA, HODGES JC, TAYLOR DG: Renal hemodynamic and excretory responses to PD 123319 and Losartan. Nonpeptide AT₁ and AT₂ subtype-specific angiotensin II ligands. *J Pharmacol Exp Ther* 262:1154–1160, 1992
 38. REMUZZI A, MALANCHINI B, BATTAGLIA C, BERTANI T, REMUZZI G: Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats. *Exp Nephrol* 4:19–25, 1996
 39. GOHLKE P, LINZ W, SCHÖLKENS BA, WIEMER G, UNGER T: Cardiac and vascular effects of long-term Losartan treatment in stroke-prone spontaneously hypertensive rats. *Hypertension* 28:397–402, 1996
 40. ITO M, OLIVERIO MI, MANNON PJ, BEST CF, MAEDA N, SMITHIES O, COFFMAN TM: Regulation of blood pressure by the type 1A angiotensin II receptor gene. *Proc Natl Acad Sci USA* 92:3521–3525, 1995
 41. MEFFERT S, STOLL M, STECKELINGS UM, BOTTARI SP, UNGER T: The AT₂ receptor inhibits proliferation and promotes differentiation in PC12W cells. *Mol Cell Endocrinol* 122:59–67, 1996
 42. KAMBAYASHI Y, BARDHAN S, TAKAHASHI K, TSUZUKI S, INUI H, HAMAKUBO T, INAGAMI T: Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. *J Biol Chem* 268:24543–24546, 1993
 43. MUKOYAMA M, NAKAJAMA M, HORIUCHI M, SASAMURA H, PRATT RE, DZAU VJ: Expression cloning of type-2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. *J Biol Chem* 268:24539–24542, 1993
 44. KANG J, POSNER P, SUMNERS C: Angiotensin II type-2 receptor stimulation of neuronal K⁺ currents involves an inhibitory GTP binding protein. *Am J Physiol* 267:C1289–C1297, 1994
 45. BOTTARI SP, KING IN, REICHLIN S, DAHLSTROEM I, LYDON N, DE GASPARO M: The angiotensin AT₂ receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate. *Biochem Biophys Res Commun* 183:206–211, 1992
 46. GRADY EF, SECHI LA, GRIFFIN CA, SCHAMBELAN M, KALINYAK JE: Expression of AT₂ receptors in the developing rat fetus. *J Clin Invest* 88:921–933, 1991
 47. METSÄRINNE KP, STOLL M, GOHLKE P, PAUL M, UNGER T: Angiotensin II is antiproliferative for coronary endothelial cells in vitro. *Pharm Pharmacol Lett* 2:150–152, 1992
 48. STOLL M, STECKELINGS UM, BOTTARI SP, UNGER T: Regulation of endothelial growth: Role of the angiotensin II AT₂-receptor. (abstract) *Circulation* 88(Suppl 4, pt 2):I–469, 1993
 49. GALLINAT S, CSIKÓS T, MEFFERT S, HERDEGEN T, STOLL M, UNGER T: The angiotensin AT₂ receptor down-regulates neurofilament M in PC12W cells. *Neurosci Lett* 227:29–32, 1997
 50. STROTH U, MEFFERT S, GALLINAT S, UNGER T: Angiotensin II and NGF differentially influence microtubule proteins in PC12W cells: Role of the AT₂ receptor. *Mol Brain Res* (in press)
 51. STECKELINGS UM, BOTTARI SP, STOLL M, WAGNER J, UNGER T: Repression of *c-fos* and *c-jun* gene expression is not part of AT₂ receptor-coupled signal transduction. *J Mol Med* (in press)
 52. NAKAYAMA M, HORIUCHI M, MORISHITA R, YAMADA T, PRATT RE, DZAU VJ: Growth inhibitory function of type 2 angiotensin II receptor: Gain of function study by *in vivo* gene transfer. (abstract) *Hypertension* 24:37, 1994
 53. SIRAGY HM, CAREY RM: The subtype-2 (AT₂) angiotensin receptor regulates renal cyclic guanosine 3',5'-monophosphate and AT₁ receptor-mediated prostaglandin E₂ production in conscious rats. *J Clin Invest* 97:1978–1982, 1996
 54. GOHLKE P, PEES C, UNGER T: AT₂ receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. *Hypertension* (in press)
 55. SHANMUGAM S, LLORENS-CORTES C, CLAUSER E, CORVOL P, GASC JM: Expression of angiotensin II AT₂ receptor mRNA during development of rat kidney and adrenal gland. *Am J Physiol* 268:F922–F930, 1995
 56. CIUFFO GM, VISWANATHAN M, SELTZER AM, TSUTSUMI K, SAAVEDRA JM: Glomerular angiotensin II receptor subtypes during development of rat kidney. *Am J Physiol* 265:F264–F271, 1993
 57. AGUILERA G, KAPUR S, FEUILLAN P, SUNAR-AKBASAK B, BATHIA AJ: Developmental changes in angiotensin II receptor subtypes and AT₁ receptor mRNA in rat kidney. *Kidney Int* 46:973–979, 1994
 58. YAMADA T, HORIUCHI M, DZAU VJ: Angiotensin II type 2 receptor mediates programmed cell death. *Proc Natl Acad Sci USA* 93:156–160, 1996
 59. GOTO M, MUKOYAMA M, SUGA S, MATSUMOTO T, NAKAGAWA M, ISHIBASHI R, KASAHARA M, SUGAWARA A, TANAKA I, NAKAO K: Growth-dependent induction of angiotensin II type 2 receptor in rat mesangial cells. *Hypertension* 30:358–362, 1997